Alembic buys UTI-focused Utility Therapeutics in USD 12 million deal

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-07-03 06:28 GMT   |   Update On 2025-07-03 06:43 GMT
Advertisement

Vadodara: Alembic Pharmaceuticals Inc., a wholly owned subsidiary of Alembic Pharmaceuticals Limited, has acquired a 100 percent stake in Utility Therapeutics Ltd, a pharmaceutical company focused on treatments for urinary tract infections (UTIs).

The strategic acquisition is aimed at marketing both USFDA-approved and under-development products owned by Utility in the United States.

In a regulatory filing with the BSE, Alembic confirmed that the acquisition will be completed within approximately 30 days. The total consideration is structured as a cash payment along with a profit share out of future profits.

Advertisement

The acquisition is valued at around USD 12 million, to be paid in a staggered manner over period of time, depending on milestone achievements.

Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI).
-“Pivya” is an FDA approved product to treat uncomplicated UTIs in the US market.
-“MEC” is a product in development for the treatment of complicated UTIs in the US market.
As a product development company they have minimal turnover in last 3 years.

Alembic stated that the the proposed acquisition of Utility (by wholly owned subsidiary i.e. Alembic Pharmaceuticals Inc.) does not fall under related party transaction.

The promoter / promoter/ promoter group are not interested in the transaction. 

Read also: Alembic Pharma bags USFDA nod for cancer injection Doxorubicin Hydrochloride Liposome

Headquartered in India, Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company. It is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.

Read also: Alembic Pharma Viraj Save resigned as Executive Vice President - Sales and Marketing

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News